Mixed Dyslipidemia Pipeline Report 2016 - Therapeutics Review of 6 Companies & Drug Profiles - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Mixed Dyslipidemia - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Mixed Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mixed Dyslipidemia and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Mixed Dyslipidemia Overview
  3. Therapeutics Development
  4. Pipeline Products for Mixed Dyslipidemia - Overview
  5. Pipeline Products for Mixed Dyslipidemia - Comparative Analysis
  6. Mixed Dyslipidemia - Therapeutics under Development by Companies
  7. Mixed Dyslipidemia - Therapeutics under Investigation by Universities/Institutes
  8. Mixed Dyslipidemia Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Mixed Dyslipidemia - Products under Development by Companies
  13. Mixed Dyslipidemia - Products under Investigation by Universities/Institutes
  14. Mixed Dyslipidemia - Companies Involved in Therapeutics Development
  • Amgen Inc.
  • CymaBay Therapeutics, Inc.
  • Hanmi Pharmaceuticals, Co. Ltd.
  • Matinas BioPharma Holdings, Inc.
  • Pfizer Inc.
  • Thetis Pharmaceuticals LLC

For more information visit http://www.researchandmarkets.com/research/fpvpqn/mixed

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Cardiovascular Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Cardiovascular Drugs